Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer |
| |
Authors: | Hofmann Francesco García-Echeverría Carlos |
| |
Institution: | Oncology Research, Novartis Institutes for BioMedical Research, Basel, Switzerland. francesco.hofmann@novartis.com |
| |
Abstract: | Clear links between cancer and cellular signaling triggered by the insulin-like growth factor-I (IGF-I) receptor (IGF-IR) and its cognate ligands (IGF-I and IGF-II) have been reported throughout the past two decades. Experimental results suggest that the pharmaceutical targeting of this signaling pathway could be beneficial for the treatment of cancer. Here, more recent advances towards potentially clinically viable strategies to interfere with the function of IGF-IR will be discussed. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|